Impact of Stainless Steel Exposure on the Oxidation of Polysorbate 80 in Histidine Placebo and Active Monoclonal Antibody Formulation

References

1. 1.↵
   1. Harris R. J.,
   2. Shire S. J.,
   3. Winter C.

   Commercial Manufacturing Scale Formulation and Analytical Characterization of Therapeutic Recombinant Antibodies. Drug Dev. Res. 2004, 61 (3), 137–154.

   OpenUrlCrossRefWeb of Science
2. 2.↵
   1. Roque A. C.,
   2. Lowe C. R.,
   3. Taipa M. A.

   Antibodies and Genetically Engineered Related Molecules: Production and Purification. Biotechnol. Prog. 2004, 20 (3), 639–654.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Zhou S.,
   2. Schöneich C.,
   3. Singh S. K.

   Biologics Formulation Factors Affecting Metal Leachables from Stainless Steel. AAPS PharmSciTech 2001, 12 (1), 411–421.

   OpenUrl
4. 4.↵
   1. Zhou S.

   Instability of Immunoglobulin G (IgG) Monoclonal Antibodies Induced by Redox-Active Metal Ions and Photo-Irradiation. University of Kansas Doctoral Dissertation, 2012.
5. 5.↵
   1. Schöneich C.

   Mechanisms of Metal-catalyzed Oxidation of Histidine to 2-oxo-histidine in Peptides and Proteins. J. Pharm. Biomedical Anal. 2000, 21 (6), 1093–1097.

   OpenUrl
6. 6.↵
   1. Lavanant H.,
   2. Hecquet E.,
   3. Hoppilliard Y.

   Complexes of L-histidine with Fe2⁺, Co2⁺, Ni2⁺, Cu2⁺, Zn2⁺ Studied by Electrospray Ionization Mass Spectrometry. International Journal of Mass Spectrometry 1999, 185, 11–23.

   OpenUrl
7. 7.↵
   1. Stroup S. D.,
   2. Conca D. M.,
   3. Lundgard R. P.,
   4. Renz M. E.,
   5. Peabody L. M.,
   6. Leigh S. D.

   Photosensitizers Form in Histidine Buffer and Mediate the Photodegradation of a Monoclonal Antibody. J. Pharm. Sci. 2011, 100 (12), 5142–5155.

   OpenUrlPubMed
8. 8.↵
   1. LaBrenz S. R.

   Ester Hydrolysis of Polysorbate 80 in mAb Drug Product: Evidence in Support of the Hypothesized Risk after the Observation of Visible Particulate in mAb Formulations. J. Pharm. Sci. 2014, 103 (8), 2268–2277.

   OpenUrlPubMed
9. 9.↵
   1. Ha E.,
   2. Wang W.,
   3. Wang Y. J.

   Peroxide Formation in Polysorbate 80 and Protein Stability. J. Pharm. Sci. 2002, 91 (10), 2252–2264.

   OpenUrlPubMed
10. 10.↵
    1. Zhang L.,
    2. Yadav D.,
    3. Demeule B.,
    4. Wang Y. J.,
    5. Mozziconacci O.,
    6. Schöneich C.

    Degradation Mechanisms of Polysorbate 20 Differentiated by ¹⁸O-labeling and Mass Spectrometry. Pharm. Res. 2016, 34 (1), 84–100.

    OpenUrl
11. 11.↵
    1. Adjimani J. P.,
    2. Asare P.

    Antioxidant and Free Radical Scavenging Activity of Iron Chelators. Toxicology Reports 2015, 2, 721–728.

    OpenUrl
12. 12.↵
    1. Kerwin B. A.

    Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: Structure and Degradation Pathways. J. Pharm. Sci. 2008, 97 (8), 2924–2935.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Yao J.,
    2. Dokuru D. K.,
    3. Noestheden M.,
    4. Park S. S.,
    5. Kerwin B. A.,
    6. Jona J.,
    7. Ostovic D.,
    8. Reid D. L.

    A Quantitative Kinetic Study of Polysorbate Autoxidation: The Role of Unsaturated Fatty Acid Ester Substituents. Pharm. Res. 2009, 26 (10), 2303–2313.

    OpenUrlPubMed
14. 14.↵
    1. Kishore R. S.,
    2. Pappenberger A.,
    3. Dauphin I. B.,
    4. Ross A.,
    5. Buergi B.,
    6. Staempfli A.,
    7. Mahler H.-C.

    Degradation of Polysorbates 20 and 80: Studies on Thermal Autoxidation and Hydrolysis. J. Pharm. Sci. 2011, 100 (2), 721–731.

    OpenUrlPubMed
15. 15.↵
    1. Kishore R. S.,
    2. Kiese S.,
    3. Fischer S.,
    4. Pappenberger A.,
    5. Grauschopf U.,
    6. Mahler H.-C.

    The Degradation of Polysorbates 20 and 80 and Its Potential Impact on the Stability of Biotherapeutics. Pharm. Res. 2011, 28 (5), 1194–1210.

    OpenUrlPubMed